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Introduction
Chemoprevention is defined as the use of pharmacological 
or natural agents that inhibit the development of a disease. In 
the case of breast cancer, the main chemopreventive agents 
used are selective estrogen receptor blockers (SERMs) and 
aromatase inhibitors (AIs) (1, 2).
Cyclooxygenase 2 (COX-2) inhibitors, non-steroidal anti-
inflammatory drugs (NSAIDs), metformin, and statins are 
drugs that have long been in clinical use. NSAIDs are used as 
anti-inflammatories, analgesics, and, in the case of aspirin, 
antithrombotics (3); metformin is used as an anti-hyperglyce-
mic (4) and in the treatment of metabolic syndrome (5) and 
polycystic ovarian syndrome (PCOS); and statins are used for 
the primary and secondary prevention of cardiovascular dis-
ease by lowering cholesterol levels (6). Therefore, the safety 
profiles and adverse reaction profiles of these drugs are well 
understood. Thus, these drugs are good clinical candidates 
for further exploration of their mechanisms of action as 
applied to chemoprevention of breast cancer (7-9). Current 
studies regarding the novel application of these drugs have 
been critically analyzed with respect to their potential use in 
breast cancer chemoprevention. However, more research is 
needed to prove that these studies were adequately powered 
and thus are of good statistical significance, so that the use of 
these drugs can be considered as an option for chemopre-
vention of breast cancer in clinical practice.
Search strategy
The papers used as references in this review were identi-
fied using relevant keywords in related search engines such 
as Pubmed and Google Scholar, after performing a broader 
search regarding the chemoprevention of breast cancer and 
finding mentions of these drugs in other documents. The 
search terms used to identify these sources include “breast 
neoplasms,” “breast cancer,” “NSAIDs,” “aspirin,” “COX-2 
inhibitors,” “COX2 inhibitors,” “cyclooxygenase 2 inhibitors,” 
“metformin,” “statins,” and “HMG-CoA reductase inhibitors.”
The search results were then filtered, analyzed, and used as 
references in compiling this review.
Non-steroidal anti-inflammatory drugs (NSAIDs)
Various epidemiological studies have been conducted to 
establish a relationship between the use of NSAIDs and the 
incidence of breast cancer (10-12). The results of these stud-
ies are inconsistent; however, this inconsistency is most likely 
due to the fact that tumors have variable molecular properties 
(13). 
All NSAIDs, such as aspirin and ibuprofen, inhibit both cyclo-
oxygenase enzymes, largely with little or no selectivity for 
either enzyme. Aspirin irreversibly inhibits cyclooxygenase, 
while ibuprofen and other NSAIDs are reversible inhibitors.
A meta-analysis has been conducted, focusing mainly on 
the effects of aspirin and ibuprofen (14). This meta-analysis 
included 16 case-control studies, 18 cohort studies, 3 case-
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control studies nested in well-defined cohorts, and one clinical 
trial, all of which were performed between 1966 and 2008, 
examining the association between the use of NSAIDs and the 
risk of breast cancer. The results of these studies were pooled 
and statistically analyzed separately for aspirin and ibuprofen. 
The conclusions of this meta-analysis were that aspirin use 
decreased the risk of breast cancer. It was also noted that high 
intake of aspirin did not strengthen this relationship. Similarly, 
use of ibuprofen led to a decrease in the risk of breast cancer; 
however, higher intake of ibuprofen did not strengthen this 
association (14). 
This analysis also considered the effects that genetic poly-
morphisms of the COX-2 gene might have on these results; 
for example, the COX-2.847 mutation is associated with an 
even lower risk of breast cancer among patients using aspirin. 
Overall, NSAID use was associated with a lower risk of develop-
ing breast cancer. 
More recently, the relationship of aspirin and ibuprofen use with 
the risk of breast cancer has been re-examined in the context 
of the different molecular subtypes of cancer (15). A total of 
26,580 menopausal women aged 59 to 77 years were involved 
in this analysis. During follow-up through 2005, 1581 cases of 
breast cancer were observed. Estrogen receptor (ER) status 
was available for 1262 of these patients; 1060 were ER posi-
tive, and 202 were ER negative. Progesterone receptor status 
was available for 1237 cases; 910 were progesterone receptor 
positive, and 327 were progesterone receptor negative. The 
women were divided into groups based on frequency of NSAID 
intake. It was found that women who regularly took aspirin had 
an approximately 20% lower risk of breast cancer than those 
who did not. In this study, higher frequency of aspirin intake 
was associated with lower risk (15), which contrasts with the 
results from the 2008 meta-analysis. These inverse associa-
tions of aspirin use were observed for ER+, ER-, PR+, and PR- 
tumors, with the greatest correlations observed for ER+ and 
PR+ tumors. However, in this study, no association was found 
between intake of non-aspirin NSAIDs and risk of breast cancer. 
One major limitation of this study was that the type of non-
aspirin NSAID used was not specified; this may have masked 
any association between the intake of particular non-aspirin 
NSAIDs, such as ibuprofen, and the risk of breast cancer (15). It 
was further suggested that this difference is due to the fact that 
aspirin is an irreversible inhibitor of COX-2, while non-aspirin 
NSAIDs are reversible inhibitors. 
The results of these various studies, although inconsistent 
and controversial, suggest that aspirin has chemopreventive 
potential; meanwhile, the chemopreventive potential of other 
NSAIDs remains to be clarified. Furthermore, in-depth exami-
nation of the relationship of NSAID consumption with various 
tumor subtypes, such as those in which COX-2 or epidermal 
growth factor receptor (EGFR) is upregulated, may shed light 
on the types of tumors that can be prevented with NSAIDs. 
These drugs would then be combined with other agents to 
achieve greater chemopreventive efficacy through combina-
tion treatment. 
COX-2 inhibitors 
NSAIDs not only inhibit COX-2, but also cyclooxygenase 1 
(COX-1), which is responsible for regulating normal physiologi-
cal functions; therefore, various adverse effects are associated 
with NSAID use. Side effects include stomach ulcers, nausea, 
vomiting, and prolonged bleeding after injury (16). For this 
reason, specific inhibitors of COX-2 have been developed. 
These include celecoxib and nimesulide, which are potent anti-
inflammatory agents that lack the associated adverse effects 
(16). However, a different side effect profile was noted, mostly 
related to the cardiovascular system. This includes a higher pre-
disposition to hypertension, atherosclerosis, and thrombosis, 
resulting in a higher risk of myocardial infarctions and strokes 
(17); these are conditions for which risk is already increased in 
peri- and post-menopausal females.
COX-2 is induced in inflamed tissue from its constitutively active 
isoenzyme, COX-1. It is involved in the metabolism of arachi-
donic acid into prostaglandins and thromboxanes specific to 
the inflamed tissue; this mediates local vasodilation, edema, 
pain, and fever (16). 
Because prostaglandins are crucial in mediating inflamma-
tory response and the associated pain, various inhibitors of the 
cyclooxygenase enzymes have been identified or developed; 
their main target is pain relief. 
Persistent inflammation may cause DNA damage, induce 
increased cellular proliferation to repair damaged tissue, and 
create an environment that is rich in cytokines and growth 
factors; all of these lead to tumorigenesis (18). Molecular links 
between cytokines and tumorigenesis have already been dem-
onstrated for breast cancer and other conditions (19). In fact, 
COX-2 is highly overexpressed in numerous cancers, including 
breast, liver, colorectal, lung, and esophageal cancers (20, 21). 
Blocking persistent inflammation with NSAIDs and specific 
COX-2 inhibitors may therefore prove useful in the prevention 
of tumorigenesis. 
Furthermore, a lower degree of prostaglandin synthesis leads 
to inhibition of the enzyme aromatase, which is responsible 
for the synthesis of estrogen. In fact, one of the major prosta-
glandins, PGE2, specifically induces the promoter II region on 
the aromatase gene (22). COX-2 inhibition has been shown to 
prevent estrogen-induced breast tumor formation to a greater 
extent than ibuprofen (a non-selective NSAID); thus, it dem-
onstrates selective chemopreventive potential for ER-positive 
tumors (22).
The effects of ibuprofen were compared to those of celecoxib, 
particularly in their ability to inhibit carcinogenesis induced 
by 7,12-dimethylbenz(a)anthracene (DMBA) (Sigma-Aldrich; 
Darmstadt, Germany) in female Sprague-Dawley rats (22). 
These 50-day old rats were randomized into three groups, with 
40 rats in each group. One group received powdered placebo 
with a standard diet, another group received 1500 mg/kg cele-
coxib with a standard diet, and the last group received 1500 
mg/kg ibuprofen with a standard diet. After seven days, all 
rats were given an intragastric dose of 15 mg DMBA in 1.0 mL 
of sesame seed oil. The experimental and control diets were 
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continued for 105 days before the experiment was stopped. The 
time of appearance of the first tumor in rats from each group 
was noted, while the size and location of the tumor was also 
assessed. At the end of the experiment, 127 palpable tumors 
were excised from the control rats (all adenocarcinomas) and 
61 tumors were excised from rats treated with ibuprofen (all 
adenocarcinomas), while only 18 tumors were excised from 
rats treated with celecoxib (15 were adenocarcinomas, while 
3 were non-malignant fibro-adenomas). Moreover, celecoxib 
was found to reduce the incidence of mammary cancer by 
68%, tumor burden (tumors/rat) by 86%, and tumor volume by 
81% compared to the control group. Only 13 of the 40 (32%) rats 
treated with celecoxib developed tumors, while all of the con-
trol rats (100%) developed tumors. Ibuprofen was also effective, 
but not as much as celecoxib; ibuprofen caused a 40% reduc-
tion in cancer risk, a 52% reduction in tumor burden, and a 57% 
reduction in tumor size. Moreover, the time for tumor develop-
ment was prolonged with COX-2 inhibitor use. In the control 
group, the median time for detection of a tumor was 58 days 
after DMBA administration. In the celecoxib group, the median 
time was 95 days; in the ibuprofen group, it was 86 days.
It was also noted that celecoxib and ibuprofen appeared to have 
no adverse effects on rat liver, kidneys, stomach, and intestines. 
In humans, however, there are concerns that drugs that inhibi-
tion of COX-2 can lead to severe cardiovascular adverse effects. 
Nonetheless, the use of COX-2 inhibitors in patients at low risk 
for heart disease appears to be safe (21).
The results from this experiment show that celecoxib may be a 
very useful chemopreventive agent; they also support the role 
that COX-2 inhibitors, including the general NSAID ibuprofen, 
may play in reducing the risk of breast cancer.
Metformin 
Diabetes has been associated with an increased risk of develop-
ing cancer; a recent meta-analysis involving 20 studies demon-
strated the actual relationship between diabetes and breast can-
cer (23). This meta-analysis showed that women with diabetes 
have a 20% increased risk of developing breast cancer compared 
to non-diabetic women. A more recent meta-analysis suggested 
that diabetic women have a 23% higher risk of breast cancer, 
particularly menopausal women, while diabetes was also found 
to increase breast cancer mortality overall (24). Interestingly, the 
association between diabetes and breast cancer was strongest in 
Europe, followed by America, while it was non-significant in Asia 
(24). The biochemical and molecular associations between type 
2 diabetes mellitus and breast cancer are outlined in Table 1 (25-
42), while the structure, uses, outcomes, and adverse reactions 
of metformin are shown in Table 2 (4, 5, 38, 42, 43).
Metformin increases the effectiveness of neoadjuvant chemo-
therapy in breast cancer patients (44). In one particular study, 
Table 1. Biochemical and molecular associations between type 2 diabetes mellitus and breast cancer
 Biochemical Mechanisms (24)
Insulin Insulin, which is secreted in increased amounts in type 2 diabetes, was shown to be mitogenic in breast tissue.   
 This is compounded by the fact that insulin receptors tend to be over-expressed in breast cancer cells (25, 26).  
 In fact, circulating level of C-peptide as a marker for insulin secretion has been shown to be positively associ 
 ated with risk of breast cancer in some studies (27-30).
Insulin-like growth Increase in insulin secretion is accompanied by an increase in the serum level of IGF-1, which may also 
factor-1 (IGF-1) contribute to tumor growth and thus can predict the risk of breast cancer in premenopausal women (31).
Estrogens and  Increased levels of insulin also lead to higher levels of serum estrogens and androgens (32, 33) through 
androgens inhibition of sex hormone-binding globulin (34). Increased levels of estrogen and testosterone have been  
 associated with an increased risk of breast cancer in post-menopausal women (35, 36).
 Molecular Mechanisms (37)
Insulin Receptor  IR is heterotetrameric protein consisting of four subunits; two subunits bind insulin, while the other two subunits 
(IR) span the membrane, protrude into the cytosol, and have tyrosine kinase activity. Two isoforms of the insulin  
 receptor are produced by alternative splicing: IR-A (the fetal isoform) and IR-B. In most cancers, fetal IR-A  
 predominates because it mediates mitogenic rather than metabolic effects (37).
Insulin-like growth  (IGF-1R) is 60% homologous with IR and also has tyrosine kinase activity upon ligand binding by IGF-1. It 
factor-1 receptor  promotes mitogenic, metastatic, and anti-apoptotic processes in breast cancer cells through the PI3K/Akt 
(IGF-1R) pathway. Because insulin and IGF-1 can bind to both IR and IGF-1R with different affinities, both ligands can  
 enhance growth and survival (38). 
Insulin receptor  In type 2 diabetes, insulin resistance arises from the upregulation of cytokines and derivatives of free fatty acids. 
substrate-1 (IRS-1) These lead to activation of protein kinase C-zeta (PKC-zeta), which phosphorylates insulin receptor substrate-1  
 (IRS-1), impairing its ability to activate the PI3K/Akt pathway upon ligand binding (39). Eventually, hyperglycemia 
 and high insulin levels develop. Activation of IGF-1R by these high insulin levels can therefore lead to activation  
 of the mitogenic and anti-apoptotic pathways, leading to an increased risk of cancer. Metabolic syndrome very  
 often results in these patients; this is characterized by hypertension, insulin resistance, obesity, and  
 dyslipidemia (40). 
IGF-1: insulin-like growth factor-1; IR: insulin receptor; IR-A: insulin receptor isoform A (fetal); IR-B: insulin receptor isoform B; IGF-1R: insulin-like growth 
factor-1 receptor; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; IRS-1: insulin receptor substrate-1; PKC-zeta: protein kinase C-zeta
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the pathologic complete response (pCR), i.e., the absence of 
residual tumor at the time of surgery, was assessed for these 
patients (44). The difference in pCR between the non-diabetic 
group (16%) and the non-metformin group (8%) was significant, 
as was the difference between the metformin (24%) and non-
metformin (8%) groups. In contrast, the difference between 
the non-diabetic (16%) and metformin (24%) groups, although 
numerically evident, did not attain clinical significance. This 
proved that the anti-proliferative characteristics of metformin 
impair tumor development. Moreover, because insulin use was 
twice as great in the non-metformin group compared to the 
metformin group (33% and 16%, respectively), it was observed 
that higher insulin levels were associated with decreased pCR 
(44). However, overall disease recurrence did not differ signifi-
cantly between the groups, and both diabetic groups had worse 
overall survival than the non-diabetic group (45).
Various epidemiological studies have demonstrated a lower 
incidence of mortality from cancer in diabetic patients receiving 
low-dose metformin. A large meta-analysis (46) demonstrated 
that the overall cancer rate decreased by 31% in patients tak-
ing metformin compared to patients taking other anti-diabetic 
drugs. This difference was significant for pancreatic and liver 
cancer but was not significant for colon, breast, and prostate 
cancer. 
This supports earlier results that showed that cancer incidence 
decreased by more than 50% in patients who had been taking 
metformin for over 4 years (47). In 2012, another meta-analysis 
confirmed the beneficial effects of metformin for decreasing 
the risk of cancer and reducing overall cancer mortality (48). 
The mechanisms underlying the action of metformin are com-
plex and are far from fully understood. The beneficial effects of 
metformin may be indirect (through insulin), or it may directly 
affect the proliferation and growth of cells (45). Many mecha-
nisms of metformin action have been proposed, as outlined in 
Table 3 (3, 45, 49-54).
Preclinical models show that metformin can lower the inci-
dence of breast cancer (55). Metformin affects ER+ and ER- cell 
lines as well as human epidermal growth factor receptor 2 
(HER-2) normal and abnormal cancer cell lines; it inhibits cell 
proliferation and causes cell cycle arrest at the G1 checkpoint, 
probably through reduction of cyclin D1 and E2F1 expression. 
It also inhibits MAPK, Akt, and mTOR activity in all of these 
cell lines. However, metformin does not induce apoptosis. 
Furthermore, at high doses, metformin was found to reduce 
HER-2 expression in cancer cells overexpressing HER-2; at 
lower doses, it was found to inhibit HER-2 tyrosine kinase activ-
ity (55).
As demonstrated in preclinical models, metformin at a low 
dose can inhibit the tyrosine kinase activity of the HER-2 recep-
tor; also, a high dose of metformin can downregulate HER-2 
(38). Thus, therapeutically combining metformin with the anti-
HER-2 monoclonal antibody trastuzumab may be very efficient 
to eliminate stem/progenitor cell populations with amplified 
HER-2. This is particularly due to the fact that metformin can 
prevent resistance to trastuzumab treatment; this is very often 
mediated by high levels of IGF and insulin, which bind to their 
respective receptors and induce cellular proliferation, inhibi-
tion of apoptosis, angiogenesis, and metastasis. Metformin can 
decrease circulating insulin and IGF levels and can thus disrupt 
this alternative pathway for tumor development. 
In the prevention setting, metformin can therefore regulate the 
rate of proliferation of tumor progenitor cells in premalignant 
lesions, thus preventing or delaying malignant tumor forma-
tion (38). Furthermore, by regulating proliferation of dormant 
cancer stem cells, metformin can also prevent recurrence of 
breast cancer; thus, it may be effective for secondary preven-
tion of breast cancer. 
Cancer is the second leading cause of death worldwide, while 
diabetes is the twelfth (48). Considering that the prevalence of 
diabetes is constantly increasing, the use of metformin as both 
an anti-diabetic drug as well as a chemopreventive agent for 
cancer will have numerous beneficial implications and positive 
results. 
Table 2. Metformin: Structure, uses, outcomes, and adverse reactions
 Metformin
Structure Semi-synthetic biguanide with two methyl groups attached to its nitrogen nucleus.
Uses Approved for use to treat hyperglycemia (3), metabolic syndrome (4), and PCOS (41).
Outcomes (37) Decreases glucose absorption from the gut.
 Inhibits gluconeogenesis in the liver without stimulating insulin secretion. 
 Mediates increased uptake of glucose by skeletal muscle and adipose tissue, leading to a decrease in blood  
 glucose levels. 
 Increases the affinity of the insulin receptor for insulin, thus improving insulin resistance and leading to  
 reduction in insulin levels of approximately 25% to 33% after several days. 
 Decreases circulating levels of cholesterol, LDLs, and triglycerides.
Side effects  Mild gastrointestinal effects (30%) and metallic taste (3%), which are reversible with persistent use, and 
(37, 42) decreased levels of vitamin B12 (6%). 
PCOS: polycystic ovarian syndrome; LDLs: low density lipoproteins
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Statins
The anti-atherosclerotic decrease of plasma LDL caused by 
statins through inhibition of the conversion of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate in 
cholesterol synthesis has been well studied and documented 
(56). In fact, statins are the most potent class of drugs for pri-
mary and secondary prevention of cardiovascular injury. 
Considering the concept that combining statins and estrogen 
may have synergistic effects for improving lipid profiles in post-
menopausal women, investigations have been conducted to 
determine whether statins can reduce the incidence of breast 
cancer, the most controversial adverse effect associated with 
estrogen therapy (57).
Interestingly, a variety of preclinical studies show that statins 
can not only prevent cardiovascular diseases but may also 
inhibit cancer growth and development, although the actual 
mechanisms have not yet been completely elucidated (57, 58). 
A proposed mechanism of action for statins is outlined in Figure 
1 (59); this shows the mevalonate pathway on which statins (as 
HMG CoA inhibitors) act. This is also linked to various in vitro 
and in vivo studies, which are summarized in Table 4 (57-59).
Statins can also interfere with microdomain formation in 
endothelial cells and inhibit oxidative stress pathways, both 
enzymatically and non-enzymatically. Furthermore, statins can 
upregulate endothelial nitric oxide synthase, eNOS, improving 
endothelial function (60). 
In an in vitro study, the effects of statins on the cellular pro-
liferation of breast cancer cell lines were studied, both alone 
and in combination with estradiol (57). The breast cancer cell 
lines, MCF-7 (ER+) and MDA-MB 231 (ER-), were cultured in 
the presence of the lipophilic statins atorvastatin, lovastatin, 
fluvastatin, simvastatin, and hydrophilic pravastatin, both alone 
and in combination with estrogen. The results showed that all 
statins, with the exception of pravastatin, significantly inhibited 
cellular proliferation in both cell lines after four days of culture; 
this association was dose-dependent. The inhibitory values 
Table 3. Proposed mechanisms of action of metformin
Metformin Increases AMP: ATP ratio by targeting complex I in the mitochondrial electron transport chain (48).
Activation of  Increased AMP: ATP ratio induces activation of AMPK, mediated through a variety of proteins, including the 
AMPK tumor suppressor protein LKB1, CaMKK, and TAK1.
 The tumor suppressor gene LKB1 is very commonly mutated in lung and pancreatic cancers as well as  
 melanomas. The absence of functional LKB1 in breast cancer is associated with a poor prognosis, suggesting  
 that sensitivity to metformin may be mediated by LKB1 (37). Metformin resistance may also be due to genetic  
 polymorphisms in the organic cation transporter 1, a transporter crucial for the transport of metformin, which is  
 not metabolized (49).
Activated AMPK Inhibits processes that consume ATP, such as gluconeogenesis, protein synthesis, and fatty acid synthesis. 
 Promotes processes that generate ATP, such as glycolysis and oxidation of fatty acids; because tumor cells  
 require high levels of fatty acid synthesis, this shift from anabolic pathways toward catabolic pathways partly  
 explains the anti-proliferative activity of metformin.
 Inhibits cellular proliferation (44). AMPK is involved in a complex regulatory network, integrating extracellular  
 and intracellular stimuli to control processes that are crucial to maintain tissue size. AMPK phosphorylates and  
 stabilizes the tumor suppressor protein TSC2, which interacts with the mammalian target of rapamycin (mTOR),  
 the master regulator of cellular protein synthesis (50). In this way, AMPK inhibits mTOR activity, thus inhibiting  
 tumorigenesis, cancer progression, angiogenesis, and metastasis. This provides a theoretical basis for  
 combining metformin and agents targeting the PI3K/Akt pathway to efficiently inhibit the PI3K/Akt/mTOR  
 interactive pathway and prevent tumorigenesis.
 Inhibits expression of the aromatase gene, thus decreasing local production of estrogen and reducing the risk of  
 developing hormone-dependent breast cancers.
 Chronic activation of AMPK is also believed to lead to activation of p53 and cellular senescence (51). p53 acts as  
 a metabolic checkpoint, inducing cell cycle arrest in situations of low cellular energy (52). Furthermore, active  
 p53 can inhibit glycolysis and enhance oxidative phosphorylation, preventing the Warburg effect (i.e., the  
 reprogramming of cellular metabolism toward aerobic glycolysis and away from oxidative phosphorylation, a  
 phenomenon common to approximately 60% to 90% of tumors) (52). The shift towards aerobic glycolysis in the  
 Warburg effect is required to meet the needs of constant proliferation due to enhanced metabolism and uptake  
 of glucose. In fact, this shift provides the basis for positron emission tomography, using a radioactive analog  
 of glucose to identify tumors with increased uptake and metabolism of the glucose analog. Metformin may  
 inhibit this shift if p53 is functional. However, the fact that some studies show that metformin can actually  
 enhance glycolysis through mitochondrial poisoning creates controversy, which has yet to be resolved through  
 further research. Furthermore, mutations in p53 cause metabolic alterations, leading to the Warburg  
 effect (52, 53).
AMP: adenosine monophosphate; ATP: adenosine triphosphate; AMPK: 5’ adenosine monophosphate-activated protein kinase; LKB1: liver kinase B1; 
CaMKK: calcium/calmodulin-dependent protein kinase kinase; TAK1: transforming growth factor beta-activated kinase 1; TSC2: tuberous sclerosis 
complex 2; mTOR: mammalian target of rapamycin; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; p53: cellular tumor antigen p53
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ranged from 10% to 90%; the inhibition was greater in ER- cells. 
In ER+ cells, atorvastatin was a less potent inhibitor than the 
other statins. In the presence of estrogen, all statins showed 
equal inhibition of cellular proliferation in ER+ cells. However, 
the statins were not completely successful in preventing cel-
lular proliferation in the presence of stimulating estradiol (57). 
Further in vitro studies have demonstrated the ability of the lipo-
philic statins to prevent cellular proliferation in tumor cell lines 
that are hormone receptor-positive and HER-2-negative (MCF-
7), hormone receptor-negative and HER-2-positive (SKBr3), or 
double negative (MDA-231) (58). In vitro, the hydrophilic statin 
pravastatin showed no inhibitory effects on any cell line. In 
contrast, the lipophilic statins fluvastatin, lovastatin, and simv-
astatin showed significant inhibition of cell growth, particularly 
in cells with activated Ras and HER-2 pathways. Furthermore, 
response to statins appeared to be associated with cellular lev-
els of NF-κB, an anti-apoptotic mediator and transcription factor 
complex. Within four hours of statin treatment, all three cell 
lines showed significant reductions in cellular p-MEK1/2 levels, 
a key player in the Ras-Raf-MEK-MAPK pathway that drives cel-
lular proliferation. However, this decrease was transient, and 
p-MEK1/2 levels began to increase after 12 hours. In SKBr3 cells, 
levels of activated NF-κB decreased to approximately 70% after 
48 hours; AP-1 levels also decreased. Moreover, levels of cyclin 
D1 were seen to decrease, thus halting the cell cycle, while the 
levels of apoptotic mediators, mainly caspases (58). 
In an in vivo study, mice inoculated with MCNeuA cells (HER-
2+, ER-) benefitted from oral treatment of simvastatin at 1 to 
2 mg/kg body weight daily (equivalent to approximately 5 to 
10 mg daily in humans) (58). Tumors from mice treated with 
statins appeared to be richer in caspases, showing enhanced 
apoptosis (58).
Epidemiological studies provide conflicting evidence. Numerous 
studies have demonstrated that statin use is associated with a 
lower risk of developing cancer (61-64), while other studies 
describe an increased risk (65, 66). Bonovas et al. (67) conduct-
ed a meta-analysis of 7 randomized trials and 9 observational 
trials; they concluded that statin use did not affect the risk of 
developing breast cancer. The overall incidence of breast can-
cer was calculated to be 1.55% in the treatment group receiving 
Table 4. Effects of statins as outlined in Figure 1
Endothelial cells Interfere with microdomain formation and inhibit oxidative stress pathways, both enzymatically and  
 non-enzymatically. Statins can also upregulate endothelial nitric oxide synthase, eNOS, improving endothelial  
 function (59).
In vitro breast  In an in vitro study, the effects of statins on cellular proliferation of breast cancer cell lines were studied, both 
cancer cells alone and in combination with estradiol (56). The breast cancer cell lines, MCF-7 (ER+ cells) and MDA-MB 231  
 (ER-), were cultured in the presence of the lipophilic statins atorvastatin, lovastatin, fluvastatin, and simvastatin,  
 as well as the hydrophilic statin pravastatin, both alone and in combination with estrogen.
 The results showed that all statins, with the exception of pravastatin, significantly inhibited cellular proliferation  
 in both cell lines after four days of culture; this association was dose-dependent. The inhibitory values ranged  
 from 10% to 90%, and the inhibition was greater in ER- cells. In ER+ cells, atorvastatin was a less potent inhibitor 
 than the other statins. 
 In the presence of estrogen, all statins equally inhibited cellular proliferation in ER+ cells. However, the statins  
 were not completely successful in preventing cellular proliferation in the presence of stimulating estradiol (56).
 Further in vitro studies demonstrate the ability of the lipophilic statins to prevent cellular proliferation in tumor  
 cell lines that are hormone receptor-positive and HER-2-negative (MCF-7), hormone receptor-negative and  
 HER-2-positive (SKBr3), and double negative (MDA-231) (57). 
 In vitro, the hydrophilic statin pravastatin shows no inhibitory effect on any cell lines. In contrast, the lipophilic  
 statins fluvastatin, lovastatin, and simvastatin show significant cell growth inhibition, particularly in cells with  
 activated Ras and HER-2 pathways. 
 Furthermore, response to statins appears to be associated with cellular levels of NF-κB, an anti-apoptotic  
 mediator and transcription factor complex. Within four hours of statin treatment, all three cell lines showed  
 significant reductions in cellular p-MEK1/2 levels; these are key factors in the Ras-Raf-MEK-MAPK pathway,  
 which drives cellular proliferation. However, this decrease was transient, and the levels began to increase after  
 12 hours. In SKBr3 cells, levels of activated NF-κB decreased to approximately 70% after 48 hours, and AP-1  
 levels also decreased. Moreover, cyclin D1 levels were seen to decrease, thus halting the cell cycle, while the  
 levels of apoptotic mediators, mainly caspases (57).
In vivo (mice  In vivo, mice inoculated with MCNeuA cells (HER-2+, ER-), benefit from oral treatment of simvastatin at 1 to 2 
inoculated with  mg/kg body weight daily (equivalent to approximately 5 to 10 mg daily in humans) (57). Tumors from mice 
MCNeuA cells) treated with statins appeared to be richer in caspases, showing enhanced apoptosis (57).
eNOS: endothelial nitric oxide synthase; ER: estrogen receptor; MCF-7: Michigan Cancer Foundation-7 cell line; MDA-MB 231: cell line with breast ad-
enocarcinoma metastases derived from pleural effusion; HER-2: human epidermal growth factor receptor 2; SKBr3: cell line with breast adenocarci-
noma metastases derived from pleural effusion; Ras: rat sarcoma gene; NF-κB: nuclear factor κB; Raf: rapidly accelerated fibrosarcoma kinase; MEK: 
mitogen-activated protein kinase kinase; MAPK: mitogen-activated protein kinase; MCNeuA: mammary carcinoma from Neu transgenic mouse A
J Turk Ger Gynecol Assoc 2016; 17: 214-23
Micallef et al.
Novel applications of common drugs for chemoprevention 219
statins (132 cases) and 1.43% in the non-treatment group (122 
cases). This difference was not found to be statistically signifi-
cant. However, the trials included in this meta-analysis mainly 
focused on the effects of statins on cardiovascular disease; 
the dosages were set only in this regard, and follow-up was 
relatively short. The effects of long-term statin use and the inci-
dence of breast cancer could not be identified, which may have 
affected the observed association between statin use and risk 
of breast cancer. Furthermore, this meta-analysis included the 
use of both lipophilic and hydrophobic statins; the latter cannot 
Figure 1. Proposed mechanism of action of statins (59)
Acetyl CoA
HMG CoA Reductase
HMG CoA
Mevalonate
Rac Rho Ras
Series of
Isoprenoids
Endothelial
cells
In vivo studies
(mice inoculated with
MCNeuA cells)
In vitro studies on
breast cancer cells
Variety of cellular signaling pathways mediating cellular
proliferation, cellular metabolism as well as cell-to-cell adhesion
Inhibiton of formation of these
isoprenoid intermediates through
statin use may prevent the
tumorigenic changes associated with
these pathways.
This could therefore possibly be one
mechanism of action through which
statins exert their chemopreventive
action.
Statins
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permeate the cell membrane and thus do not exert activity on 
cellular proliferation and motility. This may have also led to the 
calculated lack of association between statin use and risk of 
breast cancer. 
More recently, a trial was performed to test the chemopre-
ventive abilities of fluvastatin in women with diagnosed DCIS 
or stage 1 breast carcinoma. Patients were randomized to 
receive either 80 mg daily or 20 mg daily of fluvastatin for 3 to 6 
weeks prior to surgery. The results showed that fluvastatin was 
most effective in patients with high grade (poorly differenti-
ated) tumors. The proliferation of these tumors decreased by a 
median of 7.2%, while in low grade tumors, this decrease was 
only 0.3%; the difference between the two was statistically sig-
nificant. Overall, tumor apoptosis increased in 38% of patients, 
remained the same in 41%, and decreased in 21%; high grade 
tumors showed an increase in apoptosis (68).
The preclinical, clinical, and epidemiological results show that 
statins can likely reduce the incidence of breast cancer and 
may have anti-tumor potential. However, controversy persists. 
Further investigation is still required to identify whether statin 
use is truly associated with reduced incidence of breast cancer, 
the magnitude of this association, and the class of patients in 
which it is most likely to be prevalent.
In conclusion, because the abovementioned drugs have differ-
ent mechanisms of action than the endocrine drugs currently 
used as chemopreventive agents (mainly SERMs and AIs), they 
may be useful as chemopreventive agents in non-responders to 
conventional chemoprevention. This makes sense, especially 
when considering that these same drugs are also being used 
to treat concurrent, prevalent conditions such as diabetes 
and hyperlipidemia. However, further studies to evaluate the 
chemopreventive potency of these drugs compared to current 
chemopreventive strategies are required to clarify this contro-
versial issue. These studies may associate these drugs with 
chemopreventive benefits in breast cancer and may also iden-
tify which patient groups are likely to benefit from this novel 
application of these drugs. The desired result would be the 
clinical implementation of these further studies, thus providing 
another mechanism of chemoprevention of breast cancer and 
reducing polypharmacy in the respective patients; thus, the 
instance of adverse drug reactions and drug-drug interactions 
would decrease.
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